These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 9314567)
41. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440 [TBL] [Abstract][Full Text] [Related]
42. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489 [TBL] [Abstract][Full Text] [Related]
46. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105 [TBL] [Abstract][Full Text] [Related]
47. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity. Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848 [TBL] [Abstract][Full Text] [Related]
48. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048 [TBL] [Abstract][Full Text] [Related]
49. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. Minami T; Nakanishi Y; Izumi M; Harada T; Hara N J Immunother; 2003; 26(5):420-31. PubMed ID: 12973031 [TBL] [Abstract][Full Text] [Related]
50. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. Prasad SJ; Farrand KJ; Matthews SA; Chang JH; McHugh RS; Ronchese F J Immunol; 2005 Jan; 174(1):90-8. PubMed ID: 15611231 [TBL] [Abstract][Full Text] [Related]
51. [Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas]. Yu JB; Feng ZX; Zhan RY Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 36(6):592-7. PubMed ID: 18067234 [TBL] [Abstract][Full Text] [Related]
52. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X. Jung ID; Shin SJ; Lee MG; Kang TH; Han HD; Lee SJ; Kim WS; Kim HM; Park WS; Kim HW; Yun CH; Lee EK; Wu TC; Park YM J Immunol; 2014 Aug; 193(3):1233-45. PubMed ID: 24990079 [TBL] [Abstract][Full Text] [Related]
53. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. Klein C; Bueler H; Mulligan RC J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863 [TBL] [Abstract][Full Text] [Related]
54. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide]. Zhang W; He L; Cao X Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032 [TBL] [Abstract][Full Text] [Related]
55. Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells. Kato M; Nakamura Y; Suda T; Ozawa Y; Inui N; Seo N; Nagata T; Koide Y; Kalinski P; Nakamura H; Chida K Cancer Immunol Immunother; 2011 Jul; 60(7):1029-38. PubMed ID: 21519830 [TBL] [Abstract][Full Text] [Related]
56. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821 [TBL] [Abstract][Full Text] [Related]
57. Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell. Chen J; Guo XZ; Li HY; Wang D; Shao XD Exp Biol Med (Maywood); 2015 Oct; 240(10):1310-8. PubMed ID: 25736302 [TBL] [Abstract][Full Text] [Related]
58. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424 [TBL] [Abstract][Full Text] [Related]
59. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma. Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266 [TBL] [Abstract][Full Text] [Related]
60. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma. Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]